论文信息 - A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G). - 字舞流文

A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G).

M. Ando | E. Baba | I. Hyodo | K. Muro | S. Morita | K. Taira | K. Murata | N. Boku | T. Moriwaki | T. Tamura | S. Ueda | T. Tsushima | T. Denda | Y. Tsuji | K. Yamazaki | M. Nagase | H. Tamagawa | M. Tsuda | T. Esaki | T. Tsuda